Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIM NASDAQ:LXRX NASDAQ:RGLS NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ALXRXLexicon Pharmaceuticals$1.07$0.90$0.28▼$2.18$386.80M1.133.43 million shs1.14 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AXOMAXOMA Royalty$24.77-0.4%$25.71$18.35▼$35.00$297.74M0.9335,060 shs20,821 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%-0.36%LXRXLexicon Pharmaceuticals0.00%-2.73%+16.82%+57.21%-52.44%RGLSRegulus Therapeutics0.00%0.00%0.00%+3.95%+353.33%XOMAXOMA Royalty-0.44%-4.10%-5.13%+1.85%-7.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals2.3945 of 5 stars3.23.00.00.01.52.50.6RGLSRegulus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA Royalty3.9209 of 5 stars3.54.00.03.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.40Hold$3.67242.68% UpsideRGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideXOMAXOMA Royalty 3.00Buy$69.50180.58% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, ALIM, LXRX, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30LXRXLexicon Pharmaceuticals$31.21M12.39N/AN/A$0.40 per share2.68RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AXOMAXOMA Royalty$13.05M22.72N/AN/A$6.95 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%8/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)Latest RGLS, ALIM, LXRX, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RGLSRegulus Therapeutics-$0.23N/AN/AN/AN/AN/A8/12/2025Q2 2025XOMAXOMA Royalty-$0.12N/AN/AN/A$9.39 millionN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.07N/AN/AN/A$4.87 millionN/A5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62LXRXLexicon Pharmaceuticals0.482.222.22RGLSRegulus TherapeuticsN/A16.3116.31XOMAXOMA Royalty1.185.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%LXRXLexicon Pharmaceuticals74.70%RGLSRegulus Therapeutics92.38%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%LXRXLexicon Pharmaceuticals13.90%RGLSRegulus Therapeutics4.35%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableLXRXLexicon Pharmaceuticals140361.49 million311.25 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableRGLS, ALIM, LXRX, and XOMA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades XOMA Royalty (NASDAQ:XOMA) to BuyJuly 28, 2025 | americanbankingnews.comXOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?July 26, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Upgraded by Wall Street Zen to "Buy" RatingJuly 26, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average - Here's What HappenedJuly 18, 2025 | marketbeat.comResearch non-profit to acquire embattled Essa in Xoma Royalty-backed dealJuly 14, 2025 | fiercebiotech.comFESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionJuly 14, 2025 | prnewswire.comXOMA Royalty (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average - Here's WhyJuly 10, 2025 | marketbeat.comAcuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)July 2, 2025 | marketbeat.comTop biotech deals in June 2025July 2, 2025 | labiotech.euLXOMA Royalty to Buy Turnstone BiologicsJune 27, 2025 | marketwatch.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comXOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger DealJune 27, 2025 | quiverquant.comQTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightJune 27, 2025 | globenewswire.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?June 24, 2025 | zacks.comXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | investing.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | globenewswire.comPositive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy RatingMay 29, 2025 | tipranks.comXOMA boosts stake in anti-CD38 antibody with $30 million dealMay 28, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, ALIM, LXRX, and XOMA Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Lexicon Pharmaceuticals NASDAQ:LXRX$1.07 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+0.93%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.XOMA Royalty NASDAQ:XOMA$24.77 -0.11 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.73 -0.04 (-0.16%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
